FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying

Go back to FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying
(NASDAQ: PASG) Delayed: 16.69 -0.39 (2.28%)
Previous Close $17.08    52 Week High
Open $16.73    52 Week Low
Day High $17.62    P/E N/A 
Day Low $16.12    EPS
Volume 196,763       

(NASDAQ: PASG) Delayed: 16.69 -0.39 (2.28%)
Previous Close $17.08    52 Week High
Open $16.73    52 Week Low
Day High $17.62    P/E N/A 
Day Low $16.12    EPS
Volume 196,763